For Participants
Registry collects contact info, consent, and treatment history. Participants complete online questionnaires pre/post-treatment and follow-ups at 3 and 12 months.

The registry collects contact info, consent, and treatment history. Participants complete online questionnaires pre/post-treatment and follow-ups up to 24 months post-treatment. Participation in the registry is completely voluntary but allows your clinician to monitor your progress through treatment in addition to contributing to a real world monitoring of the efficacy (how well the treatment works) and safety of psychedelic-assisted psychotherapy.

Once referred by your treating clinician, the following processes will occur:

  1. After your treating clinician has referred you to the registry, you will receive an email with a link. Clicking on the link will direct you to the online REDCap platform, which contains the Participant Information and Consent Form (PICF). You should read the information sheet and ensure that you understand everything contained in it prior to signing the consent form. Before you sign, if you have any questions you can contact the team at papregistry.smp@anu.edu.au
    1. If you consent to participate, you will be sent an email containing the link to the registry questionnaires, which will ask you a variety of questions about demographics, your current symptoms, and expectations of treatment, among others.
    2. If you decide not to consent to participate, your details will be removed from our database and no further communication will be received from us. Deciding not to participate will not affect your access to treatment and your treatment can proceed as planned.
  2. If you have consented to participate, you will be sent a series of questionnaires before, during, and after your treatment with a follow-up period ranging from 12 to 24 months, depending on which treatment you are receiving. For a schedule of data collection timepoints, please see the lists below.

Psychedelic-Assisted Psychotherapy

Participants will be asked to complete online questionnaires at multiple timepoints. For those receiving psychedelic-assisted psychotherapy with psilocybin or MDMA, the schedule of data collection is as follows:

  1. Baseline
  2. Pre-psychedelic (before 1st dosing session)
  3. Between dosing 1 and 2
  4. Between dosing 2 and 3
  5. Post-psychedelic treatment (after final dosing session)
  6. Post-final integration (after final integration session)
  7. 3-month follow up (from final integration date)
  8. 6-month follow-up (from final integration date)
  9. 9-month follow-up (from final integration date)
  10. 12-month follow-up (from final integration date)

Ketamine Treatment and Ketamine-Assisted Psychotherapy

For those receiving ketamine treatment or ketamine-assisted psychotherapy, the schedule of data collection is as follows:

  1. Baseline
  2. Week 2 follow up
  3. Week 4 follow up
  4. Week 6 follow up
  5. Week 8 follow up
  6. 3-month follow up
  7. 6-month follow up
  8. 9 month follow up
  9. 12-month follow up
  10. 18 month follow up
  11. 24 month follow up

Communication of Results

You will be asked during the baseline questionnaire whether you would like to share the results of the questionnaires with your treating clinician. This will be provided to them as a simple table with the questionnaire completed, total score, and date it was completed. These will only be sent to your doctor if you consent and select “Yes” for this question. You should check with your treating team whether they will need these results or not if you are unsure.

If you have any questions about this, you can contact the Registry at papregistry.smp@anu.edu.au